Regadenoson: uses, dosing, side effects & brands
Regadenoson is a pharmacologic cardiac stress test agent sold in the U.S. under 2 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Pharmacologic Cardiac Stress Test Agent
- Available as
- Injectable
- Sold as
- 2 products — Lexiscan and Regadenoson
- Prescription?
- Prescription only
- Generic available?
- Yes
How regadenoson is dosed
From the FDA label for Lexiscan (application NDA022161). Other regadenoson products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dose of LEXISCAN is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds. • Patients should be instructed to avoid consumption of any products containing methylxanthines, including caffeinated coffee, tea or other caffeinated beverages, caffeine-containing drug products, aminophylline and theophylline for at least 12 hours before a scheduled radionuclide MPI [ see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 ) ]. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer LEXISCAN if it contains particulate matter or is discolored. • Administer LEXISCAN as an intravenous injection within 10 seconds into a peripheral vein using a 22 gauge or larger catheter or needle. • Administer a 5 mL saline flush immediately after the injection of LEXISCAN. • Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as LEXISCAN. • The recommended dose of LEXISCAN is 5 mL (0.4 mg regadenoson) administered as an intravenous injection within 10 seconds; followed immediately by saline flush and radiopharmaceutical ( 2 ).
Regadenoson side effects
The following adverse reactions are discussed in more detail in other sections of the labeling. • Myocardial Ischemia [ see Warnings and Precautions ( 5.1 ) ] • Sinoatrial and Atrioventricular Nodal Block [ see Warnings and Precautions ( 5.2 ) ] • Atrial Fibrillation/Atrial Flutter [ see Warnings and Precautions ( 5.3 ) ] • Hypersensitivity, Including Anaphylaxis [ see Warnings and Precautions ( 5.4 ) ] • Hypotension [ see Warnings and Precautions ( 5.5 ) ] • Hypertension [ see Warnings and Precautions ( 5.6 ) ] • Bronchoconstriction [ see Warnings and Precautions ( 5.7 ) ] • Seizure [ see Warnings and Precautions ( 5.8 ) ] • Cerebrovascular Accident (Stroke) [ see Warnings and Precautions ( 5.9 ) ] The most common (incidence ≥ 5%) adverse reactions to LEXISCAN are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During clinical development, 1,651 patients were exposed to LEXISCAN, with most…
Who shouldn’t take regadenoson
Do not administer LEXISCAN to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless these patients have a functioning artificial pacemaker [ see Warnings and Precautions ( 5.2 ) ]. Do not administer LEXISCAN to patients with: • Second- or third-degree AV block, or • sinus node dysfunction unless the patients have a functioning artificial pacemaker ( 4 ).
Regadenoson drug interactions
No formal pharmacokinetic drug interaction studies have been conducted with LEXISCAN. • Methylxanthines, e.g., caffeine, aminophylline and theophylline, interfere with the activity of LEXISCAN ( 7.1 , 12.2 ). • Aminophylline may be used to attenuate severe and/or persistent adverse reactions to LEXISCAN ( 7.1 , 10 ). • Dipyridamole may increase the activity of LEXISCAN. When possible, withhold dipyridamole for at least two days prior to LEXISCAN administration ( 7.1 ). 7.1 Effects of Other Drugs on LEXISCAN • Methylxanthines (e.g., caffeine, aminophylline and theophylline) are non-specific adenosine receptor antagonists that interfere with the vasodilation activity of LEXISCAN [ see Clinical Pharmacology ( 12.2 ) and Patient Counseling Information ( 17 ) ]. Patients should avoid consumption of any products containing methylxanthines as well as any drugs containing theophylline or aminophylline for at least 12 hours before LEXISCAN administration. Aminophylline may be used to attenuate severe or persistent adverse reactions to LEXISCAN [ see Overdosage ( 10 ) ]. • In clinical studies, LEXISCAN was administered to patients taking other cardioactive drugs (i.e., β-blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without reported adverse reactions or apparent effects on efficacy. • Dipyridamole may change the effects of LEXISCAN. When possible, withhold dipyridamole for at least two days prior to LEXISCAN administration. 7.2 Effect of LEXISCAN on Other Drugs Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 enzymes.
Every regadenoson product we track (2)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → |
Regadenoson recalls
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
How long regadenoson keeps
The date on a sealed pack is not the only one: some regadenoson labels start a second clock once the product is opened or mixed, as short as 10 hours.
Does regadenoson expire? The in-use limits and storage rules from its labelsRegadenoson and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for regadenoson: levels in milk, effects in breastfed infants, and the drugs it would consider insteadNo information is available on the use of regadenoson during breastfeeding. To avoid exposure of the infant to regadenoson, nursing mothers should avoid breastfeeding for 10 hours after drug administration.
National Institute of Child Health and Human Development, record revised February 15, 2025. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about regadenoson
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 496 reports naming regadenoson, and the FDA flagged 63% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- nausea61 reports
- hypotension59 reports
- dyspnoea53 reports
- chest pain36 reports
- dizziness36 reports
- headache33 reports
- unresponsive to stimuli29 reports
- bradycardia26 reports
Read these as a signal, not a rate. A report does not mean regadenoson caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 26, 2026.
Related calculators
Frequently asked questions
What is regadenoson?
Lexiscan (Regadenoson) is a pharmacologic cardiac stress test agent.
What kind of drug is regadenoson?
The FDA classifies regadenoson as a pharmacologic cardiac stress test agent. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take regadenoson with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run regadenoson against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is regadenoson sold under?
We track 2 regadenoson-containing products in the U.S.: Lexiscan and Regadenoson. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does regadenoson come in?
Across the brands we track, regadenoson is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic regadenoson?
Yes. Our catalog lists 1 generic regadenoson product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
Has regadenoson been recalled?
The FDA's Enforcement database lists 1 recall record whose product description mentions regadenoson. The most recent: Regadenoson Injection (Oct 30, 2024). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.
Cite this page
- APA
- pharmaranks. (2026, July 24). Regadenoson: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/regadenoson
- MLA
- “Regadenoson: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/regadenoson.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for regadenoson on DailyMed (NIH) ↗.